AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$LQDA

Krepp Sarah sold $1.7M of LQDA

Krepp Sarah (Chief Human Resource Officer) sold 24,880 shares of Liquidia Corp (LQDA) at $70.28 ($1.75M total) across 2 trades on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Krepp Sarah
Published Jun 15, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest concrete fact is the officer’s open-market sale details (shares, price, total value) and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

This provides incremental ownership/flow information for LQDA but does not introduce a new fundamental catalyst.

03

What to watch

Traders may overreact to insider sales; without accompanying guidance/clinical/regulatory updates, the signal is usually weak.

Relevance 5/10Novelty 5/10Timing: Filed 2026-06-15; transaction dated 2026-06-11

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia Corp (LQDA) disclosed an officer open-market sale: 24,880 shares sold by Chief Human Resource Officer Sarah Krepp under a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; treat as sentiment noise unless accompanied by other fundamental news.

Evidence & confidence

The filing is a routine Form 4 insider transaction with a stated 10b5-1 plan, reducing interpretive weight versus non-plan sales.

Market effects

Sector

No sector-level read-through; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • issuer
    Liquidia Corp

    Company whose Form 4 insider sale was disclosed.

  • insider
    Sarah Krepp

    Chief Human Resource Officer who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

zacks.com
$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

investing.com
$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

finance.yahoo.com
$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.

finance.yahoo.com